Johnson & Johnson‘s Vision business said last week that it inked a deal to acquire ophthalmalogical medical device maker TearScience for an undisclosed amount.
Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said.
TearScience has won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets, the company said.
“Dry eye is a significant unmet health need globally, and meibomian gland dysfunction is the cause for more than 60% of people living with this condition. The innovative portfolio from TearScience positively impacts the lives of patients around the world suffering from this chronic condition. These solutions, coupled with our existing contact lens and surgical portfolio, will allow us to help more patients with their vision needs, throughout their lifetime,” J&J Vision companies group chair Ashley McEvoy said in a press release.
Johnson & Johnson said the acquisition will be through its recently acquired Abbott Medical Optics division, and that it expects the acquisition to close by the end of the year.
Last month, J&J said its medical device division is rolling its Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.
By Fink Densford
Source: Mass Device
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.